Pleura and Peritoneum最新文献

{"title":"Third French Congress on Mesothelioma.","authors":"","doi":"10.1515/pp-2026-0013","DOIUrl":"https://doi.org/10.1515/pp-2026-0013","url":null,"abstract":"","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"11 2","pages":"89-98"},"PeriodicalIF":2.0,"publicationDate":"2026-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13341001/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148405552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Shear wave elastography to distinguish between hard and soft mucin in pseudomyxoma peritonei.","authors":"Carissa Vici, Nishka Tapaswi, Ashish Vaska, David L Morris","doi":"10.1515/pp-2025-0044","DOIUrl":"10.1515/pp-2025-0044","url":null,"abstract":"<p><strong>Objectives: </strong>Pseudomyxoma peritonei (PMP) is a rare peritoneal malignancy characterised by progressive accumulation of mucin within the abdomen. The gold standard of PMP treatment is cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC). BromAc^® is a mucolytic therapy developed for patients with inoperable PMP but its efficacy is reduced with hard mucin. Shear wave elastography (SWE) is an ultrasound technique that quantifies the mechanical and elastic properties of tissues. It was hypothesised that SWE could provide a preoperative, objective assessment of mucin consistency.</p><p><strong>Methods: </strong>A retrospective pilot study of patients with PMP who underwent SWE prior to CRS-HIPEC was conducted. All patients underwent elastography at a specialised radiology practice. SWE results across the four quadrants of the abdomen were compared with intraoperative assessment of mucin consistency.</p><p><strong>Results: </strong>The study yielded 12 eligible patients between Jan 2020 to Apr 2025. The mean SWE value for hard mucin was 5.9 kPa compared with 4.5 kPa for soft. This difference was not statistically significant (p=0.64).</p><p><strong>Conclusions: </strong>There is a clinical need for an objective assessment of mucin consistency in patients with PMP. While limited by its small sample size, this study found that the mean SWE result for hard mucin was slightly higher than for soft.</p>","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"11 2","pages":"83-87"},"PeriodicalIF":2.0,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13340824/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148405486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PICCOS: study protocol for pressurised intraperitoneal aerosolised chemotherapy (PIPAC) in the management of cancers of the colon, ovary and stomach: a randomised controlled, phase II trial of efficacy in peritoneal metastases.","authors":"Sadie E F Jones, Elena Brogden, Jamie Murphy, Christopher J Peters, Jonathan Frost, Richard Adams, Sarah Gwynne, Emma Hudson, Kitrick Perry, Angela Casbard, Rebecca Hamilton, Lisette Nixon, Philip Markham, Huda Mohamed, Gina Brown, Jane Blazeby, Deborah Fitzsimmons, Anuoluwa Ajakaiye, Leona M Batten, Maureen Edgar, Amy Case, Peter Kyle, Sophie Tate, Karen Arndell, Daisy Elliott, Rhiannon Macefield, David Chuter, Harry Hall, Joy Garfitt, Jared Torkington","doi":"10.1515/pp-2025-0023","DOIUrl":"10.1515/pp-2025-0023","url":null,"abstract":"<p><strong>Objectives: </strong>Peritoneal metastases (PM) represent a significant unmet need requiring urgent development of treatment options to improve patient prognosis and quality of life (QoL). A novel anti-cancer technology is Pressurised IntraPeritoneal Aerosolised Chemotherapy (PIPAC). PIPAC aims to improve target specificity of anti-cancer therapies by delivering medication as an aerosol directly to the peritoneum at laparoscopy. Early phase I/II studies suggest that PIPAC has the potential to improve treatment efficacy and cancer outcomes whilst maintaining or improving QoL through less systemic drug absorption. PICCOS aims to determine whether PIPAC can improve peritoneal progression free survival (pPFS) in patients with PM from, compared to SACT alone.</p><p><strong>Methods: </strong>PICCOS is a phase II, multi-centre, superiority, randomised controlled trial (ISRCTN 17575409). It aims to determine whether PIPAC (given alone or in combination with systemic anti-cancer therapy (SACT)) can improve peritoneal progression free survival (pPFS) as per RECIST (V1.1) in patients with PM, compared to SACT alone. Key secondary outcome measures include quality of life, safety, overall survival and progression free survival. 216 patients with non-resectable PM from colorectal cancer, platinum resistant ovarian cancer and gastric cancer will be recruited. Patients will be randomised to receive either standard of care SACT alone or PIPAC in combination with (colorectal, gastric groups) or without (ovarian group) standard of care SACT. Median pPFS will be estimated using the Kaplan-Meier method. The log-rank test, stratified by prognostic factors, will be used to compare PFS distributions.</p><p><strong>Results: </strong>PIPAC is expected to achieve improved peritoneal progression free survival for patients in comparison to those treated with standard care.</p><p><strong>Conclusions: </strong>PICCOS aims to provide much needed, high-quality evidence on the efficacy of PIPAC in treating PM.</p>","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"11 2","pages":"55-65"},"PeriodicalIF":2.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13340826/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148405514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Textbook oncologic outcomes after cytoreductive surgery and HIPEC for colorectal peritoneal metastases: a single-centre cohort analysis.","authors":"Niall Brindl, Arianna Castagna, Thilo Welsch, Mohammed Al-Saeedi, Martin Schneider, Markus Büchler, Andreas Brandl","doi":"10.1515/pp-2025-0038","DOIUrl":"10.1515/pp-2025-0038","url":null,"abstract":"<p><strong>Objectives: </strong>Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is an established treatment for selected patients with colorectal peritoneal metastases (CPM). The recently proposed concept of textbook oncologic outcomes (TOO) offers a composite benchmark for surgical quality, but its applicability and prognostic relevance in CPM remain largely unexplored.</p><p><strong>Methods: </strong>We conducted a retrospective single-centre analysis of all patients undergoing CRS and HIPEC for CPM between 2007 and 2025. Primary endpoint was overall survival (OS); secondary analyses assessed individual TOO components and associated factors.</p><p><strong>Results: </strong>Eighty-four patients met inclusion criteria (age 54.1 ± 12.1 years, PCI 5.8 ± 4.5). CC0 resection was achieved in 88.1 %, severe postoperative complications occurred in 34.5 %, and reoperation was required in 20.2 % of patients. Ninety-day mortality was 1.2 %. Complete TOO was achieved in 14.3 % of patients as only 31/84 were recommended adjuvant chemotherapy. Median OS was 39.2 months. Absence of reoperation (p=0.02), and negative lymph node status (p=0.04) were significantly associated with improved OS.</p><p><strong>Conclusions: </strong>TOO was achieved in <50 % of patients, mainly due to the absence of adjuvant chemotherapy. Absence of reoperation was associated with survival, suggesting its validity as quality indicator. Refinement of TOO definitions, incorporating patient-centred recovery measures, may improve their applicability.</p>","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"11 2","pages":"73-82"},"PeriodicalIF":2.0,"publicationDate":"2026-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13340831/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148405522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Malignant bowel obstruction related to advanced peritoneal metastases: survival outcomes of surgical treatment.","authors":"Susanna Scarsi, Hugo Teixeira Farinha, Amaniel Kefleyesus, Martin Hübner, Daniel Clerc","doi":"10.1515/pp-2025-0024","DOIUrl":"10.1515/pp-2025-0024","url":null,"abstract":"<p><strong>Objectives: </strong>Malignant bowel obstruction (MBO) caused by advanced peritoneal metastases (PM) carries a poor prognosis. Surgical intervention may be the only therapeutic option in selected cases, but operative risks must be carefully balanced against potential benefits. This study aimed to evaluate the outcomes of patients undergoing surgery for MBO secondary to PM.</p><p><strong>Methods: </strong>Single-centre retrospective analysis of consecutive patients operated for MBO of various origins between 2016 and 2021. The primary outcome was overall survival (OS). Secondary outcomes included postoperative morbidity, resumption of systemic chemotherapy, and incidence of re-obstruction.</p><p><strong>Results: </strong>A total of 27 patients (median age 64 years, 67 % female) were included. Median peritoneal cancer index (PCI) was 32, and ascites was present in 16 patients (59 %). Surgical resolution of obstruction was achieved in 24 patients (88 %) via bowel resection (n=10), internal bypass (n=7), stoma formation (n=5), or adhesiolysis (n=2). Severe morbidity occurred in 26 %, with no postoperative mortality. Five patients (19 %) required reoperation, and three (11 %) developed enterocutaneous fistulae. Median OS was 4.0 months (IQR 9.4). Survival rates at 3, 6, and 12 months were 56 , 37, and 26 %, respectively. Postoperative systemic chemotherapy was resumed in 19 patients (70 %), significantly more often among those surviving >6 months (p=0.02). Re-obstruction occurred in 14 patients (52 %).</p><p><strong>Conclusions: </strong>Surgery is a feasible and valid therapeutic option for selected patients with MBO due to advanced PM. Despite considerable morbidity, most patients are able to resume systemic chemotherapy, which may contribute to improved survival outcomes.</p>","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"11 2","pages":"67-72"},"PeriodicalIF":2.0,"publicationDate":"2026-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13340827/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148405558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multicenter dose de-escalation phase I trial of pressurized intraperitoneal aerosolized chemotherapy (PIPAC) nab-paclitaxel and cisplatin in combination with systemic nab-paclitaxel in recurrent ovarian cancer patients: trial in progress.","authors":"Vinita Popat, Paul H Frankel, Nora H Ruel, Susan E Yost, Sue Chang, Edward Wang, Jeannine Villella, Jill Whyte, Richard L Whelan, Melissa Eng, Raechelle Tinsley, Tim Synold, Ernest Han, Mihae Song, Joshua Cohen, Mustafa Raoof, Thanh Hue Dellinger","doi":"10.1515/pp-2025-0036","DOIUrl":"10.1515/pp-2025-0036","url":null,"abstract":"<p><strong>Objectives: </strong>Ovarian cancer (OC) often presents with peritoneal metastases (PM) which contribute significantly to morbidity and treatment resistance. Pressurized intraperitoneal aerosolized chemotherapy (PIPAC) has emerged as a promising modality for locoregional drug delivery in peritoneal surface malignancies. Historically, combined intraperitoneal (IP) and intravenous (IV) cisplatin and paclitaxel regimens have demonstrated activity in first-line OC treatment. PIPAC nab-paclitaxel and cisplatin with systemic nab-paclitaxel holds promise as a safe and effective therapy, but has not been explored in OC.</p><p><strong>Methods: </strong>This ongoing, dose de-escalation, single-arm phase I study evaluates triplet bidirectional chemotherapy with a safety lead-in (NCT04329494). The study evaluates the safety and tolerability of a 28-day cycle of Day 1 PIPAC nab-paclitaxel 90 mg/m² and cisplatin 15 mg/m² in combination with Days 8 and 15 IV nab-paclitaxel 100 mg/m² for three cycles in recurrent OC patients with unresectable PM.</p><p><strong>Results: </strong>Enrollment is ongoing at U.S. academic centers. The primary endpoints are dose-limiting toxicities and adverse events. Secondary endpoints include radiographic (RECIST v1.1), histologic, and surgical response, progression-free and overall survival, and post-operative complications.</p><p><strong>Conclusions: </strong>This study investigates the safety, feasibility, and preliminary activity of the combination of PIPAC and systemic IV chemotherapy in recurrent OC patients to determine efficacy and safety for a future Phase II trial.</p>","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"11 1","pages":"39-48"},"PeriodicalIF":2.0,"publicationDate":"2025-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13001819/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147499437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The utility of a pleural carcinomatosis score for assessing resectability.","authors":"Gabrielle Drevet, Yaniss Belaroussi, Valentin Soldea, Erik Kovacs, Renaud Grima, Jean-Michel Maury, François Tronc","doi":"10.1515/pp-2025-0033","DOIUrl":"10.1515/pp-2025-0033","url":null,"abstract":"<p><strong>Objectives: </strong>Malignant pleural effusion is a common evolution of various cancers and is associated with poor prognosis and quality of life. Currently, the surgical approach is mainly palliative, involving videothoracoscopic talc pleurodesis or the insertion of indwelling pleural catheters. No surgical options with a curative intent are validated for this indication. The aim of our study was to evaluate a score for assessing resectability in pleural carcinomatosis.</p><p><strong>Methods: </strong>122 consecutive patients with recurrent symptomatic pleural effusion, referred to our thoracic surgery department for a surgical exploration of the pleura, were prospectively included. Each patient underwent a detailed description of videothoracoscopic findings, which were summarized in our pleural carcinomatosis score. Resectability was then discussed in our surgical staff meeting.</p><p><strong>Results: </strong>Eighty patients (65.6 %) were diagnosed with metastatic pleural spread, while 42 patients were diagnosed with benign pleural disease (34.4 %). Patients diagnosed with benign pleural effusion had a median score of 2, and 29 patients (69 %) were considered resectable. Patients diagnosed with malignant pleural effusion had a median score of 11, and only 13 patients (16.2 %) were considered resectable. Those deemed resectable had a median score of 5. The threshold for resectability in our score was set at 6.</p><p><strong>Conclusions: </strong>The meticulous exploration of the pleura and calculation of the pleural carcinomatosis score could aid in selecting patients for curative-intent surgery. Patients with a score equal to or less than 6 should be discussed in a multidisciplinary tumor board where the possibility of surgery is considered.</p>","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"11 1","pages":"19-25"},"PeriodicalIF":2.0,"publicationDate":"2025-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13001818/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147499465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proposed strategy after complete LAMN (low-grade appendiceal mucinous neoplasm) resection by different RENAPE units: need for a new consensus?","authors":"Christian Mouawad, Abdelkader Taibi, Olivia Sgarbura, Dahbia Djelil, Frédéric Marchal, Isabelle Sourrouille, Diane Goere, Olivier Glehen, Gwenael Ferron, Fréderic Dumont, Thomas Courvoisier Clement, Cécile Brigand, Koceila Lamine Amroun, Karine Abboud, Laurent Villeneuve, Marc Pocard","doi":"10.1515/pp-2025-0037","DOIUrl":"10.1515/pp-2025-0037","url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate current postoperative management strategies for incidentally discovered, completely resected low-grade appendiceal mucinous neoplasms (LAMNs) within the French RENAPE network and to assess the need for a new national consensus.</p><p><strong>Methods: </strong>A national survey was conducted among RENAPE expert centers using a structured questionnaire based on standardized postoperative risk scenarios. Survey items addressed surveillance strategies, indications for reoperation, and use of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC).</p><p><strong>Results: </strong>Ninety-one percent of centers responded. All reported systematic multidisciplinary discussion, centralized pathology and imaging review, standardized imaging, and tumor marker assessment. Marked heterogeneity was observed. For low-risk patients (R0 resection, no perforation, no extra-appendiceal mucin), 50 % recommended no follow-up and 50 % proposed long-term MRI surveillance. In intermediate-risk cases (limited perforation or adjacent mucin), 80 % favored MRI follow-up, while 20 % recommended diagnostic laparoscopy or prophylactic CRS-HIPEC. In high-risk scenarios with radiologic suspicion of implants, 60% proposed early CRS-HIPEC, whereas others preferred laparoscopic assessment or surveillance.</p><p><strong>Conclusions: </strong>This survey highlights wide variation in postoperative strategies for LAMNs within RENAPE, especially in intermediate-risk cases. While consensus exists on centralized review and imaging, significant evidence gaps persist regarding prophylactic HIPEC. These findings underscore the need for harmonized, evidence-based protocols and prospective data collection.</p>","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"11 1","pages":"49-54"},"PeriodicalIF":2.0,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13001816/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147499551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High prevalence of <i>KRAS</i> and <i>GNAS</i> mutations in pseudomyxoma peritonei underscores opportunities for targeted therapeutic strategies.","authors":"Annette Torgunrud, Christin Lund-Andersen, Ben Davidson, Ina Katrine Nitschke Marcussen, Stein G Larsen, Vegar Dagenborg, Kjersti Flatmark","doi":"10.1515/pp-2025-0034","DOIUrl":"10.1515/pp-2025-0034","url":null,"abstract":"<p><strong>Objectives: </strong>Pseudomyxoma peritonei (PMP) is a rare, slow-growing cancer with few efficacious treatment options in unresectable cases. Mutations in the <i>KRAS</i> and <i>GNAS</i> oncogenes are common, but the reported frequencies vary greatly, most likely because of low tumor cellularity in peritoneal tumor samples. With treatments targeting these mutations becoming increasingly available, reliable detection of mutations is essential.</p><p><strong>Methods: </strong>The frequency of <i>KRAS</i> and <i>GNAS</i> mutations was analyzed in tumor samples from 167 patients with verified PMP using targeted DNA sequencing and/or droplet digital polymerase chain reaction. When analysis of fresh-frozen peritoneal tumor samples did not reveal mutations, macrodissected formalin-fixed samples were analyzed.</p><p><strong>Results: </strong>Mutations in cancer-related genes were detected in 98 % of the analyzed samples, with <i>KRAS</i> and <i>GNAS</i> mutated in 148 (89 %) and 139 (83 %) cases, respectively. In 48 % of the analyzed cases, the mutational diagnosis was based on primary tumor samples.</p><p><strong>Conclusions: </strong>High frequencies of <i>KRAS</i> and <i>GNAS</i> mutations support the proposed role as driver mutations and as potential therapy targets. The primary tumor may serve as an alternative source of tumor material, increasing the likelihood of detecting targetable mutations. Combined with highly sensitive analytical methods, this approach facilitates selection of patients for novel targeted therapeutic strategies.</p>","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"11 1","pages":"11-18"},"PeriodicalIF":2.0,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13001815/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147499365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preoperative chemotherapy in colorectal peritoneal metastatic disease - a real-world observational cohort study.","authors":"Peter H Cashin, Petter Frühling, Pontus Grönlund, Wilhelm Graf, Peter Nygren, Lana Ghanipour","doi":"10.1515/pp-2025-0035","DOIUrl":"10.1515/pp-2025-0035","url":null,"abstract":"<p><strong>Objectives: </strong>The effects of preoperative chemotherapy have been poorly studied in colorectal cancer with peritoneal metastases (CRC-PM). This study evaluated preoperative chemotherapy from the first multi-disciplinary team meeting (MDT) decision, focusing on the response rates, surgical outcomes, and survival.</p><p><strong>Methods: </strong>This retrospective cohort study analyzed consecutive patients with resectable or potentially resectable CRC-PM evaluated at Uppsala University Hospital's peritoneal-MDT between March 2019 and December 2023. Kaplan-Meier curves and Cox-regression analyses were used for survival analysis.</p><p><strong>Results: </strong>Of 179 patients, 81 underwent upfront surgery; 52 received doublet chemotherapy and 46 received doublet with targeted therapy. Targeted group showed a 52 % overall response rate vs. 36 % for doublet group (p=0.14), with patients selected for CRS and HIPEC at a 52 % vs. 31 % rate, respectively, p=0.086. The median overall survival was superior in the targeted group than in the doublet group (intention-to-treat with all patients included): 21 (95 %CI: 18-35) vs. 17 (95 %CI: 14-22) months (p=0.027). The VEGF-targeted therapy outperformed EGFR-targeted therapy: 32 (95 %CI: 21-Not reached) vs. 15 (95 %CI: 11-40) months (p=0.042).</p><p><strong>Conclusions: </strong>Preoperative chemotherapy with targeted antibodies improves overall survival in CRC-PM in patients that are not candidates for upfront CRS and HIPEC. Bevacizumab is associated with improvement over EGFR targeted treatment in a subgroup analysis.</p>","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"11 1","pages":"1-10"},"PeriodicalIF":2.0,"publicationDate":"2025-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13001817/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147499424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}